MX2021009444A - Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. - Google Patents
Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7.Info
- Publication number
- MX2021009444A MX2021009444A MX2021009444A MX2021009444A MX2021009444A MX 2021009444 A MX2021009444 A MX 2021009444A MX 2021009444 A MX2021009444 A MX 2021009444A MX 2021009444 A MX2021009444 A MX 2021009444A MX 2021009444 A MX2021009444 A MX 2021009444A
- Authority
- MX
- Mexico
- Prior art keywords
- imidazo
- triazin
- tlr7 agonist
- amine derivatives
- stereoisomer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se divulga un derivado de imidazo[2,1-f][1,2,4]tria zin-4-amina o un estereoisómero del mismo, o una sal farmacéuticamente aceptable del mismo, útil como agonista de TLR7, y una composición farmacéutica que lo comprende. También se divulga en la presente un método para tratar el cáncer mediante el uso del derivado de imidazo[2,1-f][1,2,4]triazin-4-amina o un estereoisómero del mismo, o una sal farmacéuticamente aceptable del mismo, a manera de agonista de TLR7.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019074732 | 2019-02-07 | ||
| CN2019098757 | 2019-07-31 | ||
| CN2020073673 | 2020-01-22 | ||
| PCT/CN2020/074437 WO2020160711A1 (en) | 2019-02-07 | 2020-02-06 | Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009444A true MX2021009444A (es) | 2021-11-12 |
Family
ID=71947004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009439A MX2021009439A (es) | 2019-02-07 | 2020-02-06 | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. |
| MX2021009444A MX2021009444A (es) | 2019-02-07 | 2020-02-06 | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009439A MX2021009439A (es) | 2019-02-07 | 2020-02-06 | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20230167117A1 (es) |
| EP (2) | EP3921319B1 (es) |
| JP (2) | JP7637328B2 (es) |
| KR (2) | KR20210125026A (es) |
| CN (2) | CN113423708B (es) |
| AU (2) | AU2020218872A1 (es) |
| BR (2) | BR112021015016A2 (es) |
| CA (2) | CA3129234A1 (es) |
| IL (2) | IL285315B2 (es) |
| MX (2) | MX2021009439A (es) |
| SG (2) | SG11202108284TA (es) |
| TW (2) | TWI841679B (es) |
| WO (2) | WO2020160710A1 (es) |
| ZA (2) | ZA202105338B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020011564A (es) | 2018-05-01 | 2021-01-29 | Revolution Medicines Inc | Analogos de rapamicina unidos a c26 como inhibidores de mtor. |
| PE20252397A1 (es) | 2018-05-01 | 2025-10-10 | Revolution Medicines Inc | Analogos de rapamicina ligados a c40, c28 y c-32 como inhibidores de mtor |
| US20230167117A1 (en) | 2019-02-07 | 2023-06-01 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist |
| TW202115078A (zh) * | 2019-08-02 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 |
| TW202200589A (zh) | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| CN114057746B (zh) * | 2020-08-04 | 2025-01-28 | 百济神州(北京)生物科技有限公司 | 作为tlr7激动剂的咪唑并[2,1-f][1,2,4]三嗪-4-胺衍生物的制备 |
| CN114805392A (zh) * | 2021-01-20 | 2022-07-29 | 上海维申医药有限公司 | 大环tlr7激动剂、其制备方法、药物组合物及其用途 |
| EP4320101A2 (en) * | 2021-04-09 | 2024-02-14 | Revolution Medicines, Inc. | Synthesis of rapamycin analog compounds |
| US20240327354A1 (en) * | 2021-07-23 | 2024-10-03 | Institut National de la Santé et de la Recherche Médicale | Gram-negative bacteria efflux pump inhibitors |
| WO2023172347A1 (en) * | 2022-03-10 | 2023-09-14 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated lipid nanocarriers compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof |
| EP4531859A1 (en) | 2022-05-25 | 2025-04-09 | Revolution Medicines, Inc. | Methods of treating cancer with an mtor inhibitor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2210891A1 (en) | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| SG173617A1 (en) | 2009-02-11 | 2011-09-29 | Univ California | Toll-like receptor modulators and treatment of diseases |
| ME02656B (me) | 2009-09-21 | 2017-06-20 | Gilead Sciences Inc | 2' -fluoro supstituisani karba-nukleozidni analozi za antiviralno lečenje |
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| JP5900234B2 (ja) | 2012-08-09 | 2016-04-06 | ダイキン工業株式会社 | 加湿装置 |
| WO2014035140A2 (en) * | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| PL2906563T3 (pl) | 2012-10-10 | 2018-10-31 | Janssen Sciences Ireland Uc | Pochodne pirolo[3,2-d]pirymidyny do leczenia infekcji wirusowych i innych chorób |
| CN105367576A (zh) * | 2014-08-15 | 2016-03-02 | 正大天晴药业集团股份有限公司 | 作为tlr7激动剂的吡咯并嘧啶化合物 |
| PT3190113T (pt) | 2014-08-15 | 2021-06-17 | Chai Tai Tianqing Pharmaceutical Group Co Ltd | Compostos pirrolopirimidina utilizados como agonistas de tlr7 |
| BR112017012930A2 (pt) | 2014-12-19 | 2018-01-09 | Janssen Pharmaceutica Nv | derivados de imidazopiridazina como inibidores de pi3kbeta. |
| US20180201614A1 (en) * | 2015-05-12 | 2018-07-19 | Kalyra Pharmaceuticals, Inc. | Bicyclic compounds |
| SMT202400141T1 (it) | 2015-12-17 | 2024-05-14 | Merck Patent Gmbh | 8-ciano-5-piperidino-chinoline come antagonisti di tlr7/8 e loro usi per trattamento di disturbi immunitari |
| WO2017223414A1 (en) * | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
| US11084818B2 (en) | 2016-11-11 | 2021-08-10 | Hepo Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use |
| EP3546457B1 (en) | 2016-11-28 | 2021-07-14 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof |
| EP3636646A4 (en) | 2017-05-18 | 2020-12-09 | Jiangsu Hengrui Medicine Co., Ltd. | HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF |
| US20230167117A1 (en) | 2019-02-07 | 2023-06-01 | Beigene, Ltd. | Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist |
| TW202115078A (zh) | 2019-08-02 | 2021-04-16 | 英屬開曼群島商百濟神州有限公司 | 咪唑並[2,1-f][1,2,4]三嗪-4-胺衍生物作為tlr8促效劑 |
-
2020
- 2020-02-06 US US17/428,853 patent/US20230167117A1/en active Pending
- 2020-02-06 US US17/428,856 patent/US12281119B2/en active Active
- 2020-02-06 SG SG11202108284TA patent/SG11202108284TA/en unknown
- 2020-02-06 SG SG11202108283QA patent/SG11202108283QA/en unknown
- 2020-02-06 BR BR112021015016-1A patent/BR112021015016A2/pt unknown
- 2020-02-06 JP JP2021546210A patent/JP7637328B2/ja active Active
- 2020-02-06 WO PCT/CN2020/074436 patent/WO2020160710A1/en not_active Ceased
- 2020-02-06 AU AU2020218872A patent/AU2020218872A1/en not_active Abandoned
- 2020-02-06 CN CN202080013393.3A patent/CN113423708B/zh active Active
- 2020-02-06 WO PCT/CN2020/074437 patent/WO2020160711A1/en not_active Ceased
- 2020-02-06 EP EP20752096.6A patent/EP3921319B1/en active Active
- 2020-02-06 CA CA3129234A patent/CA3129234A1/en active Pending
- 2020-02-06 IL IL285315A patent/IL285315B2/en unknown
- 2020-02-06 MX MX2021009439A patent/MX2021009439A/es unknown
- 2020-02-06 KR KR1020217027572A patent/KR20210125026A/ko not_active Ceased
- 2020-02-06 CA CA3129178A patent/CA3129178A1/en active Pending
- 2020-02-06 MX MX2021009444A patent/MX2021009444A/es unknown
- 2020-02-06 EP EP20752173.3A patent/EP3921320B1/en active Active
- 2020-02-06 AU AU2020218383A patent/AU2020218383B2/en active Active
- 2020-02-06 JP JP2021546230A patent/JP7564112B2/ja active Active
- 2020-02-06 KR KR1020217027571A patent/KR102853071B1/ko active Active
- 2020-02-06 CN CN202080013422.6A patent/CN113454086B/zh active Active
- 2020-02-06 BR BR112021015012-9A patent/BR112021015012A2/pt not_active Application Discontinuation
- 2020-02-07 TW TW109103808A patent/TWI841679B/zh active
- 2020-02-07 TW TW109103823A patent/TWI835999B/zh not_active IP Right Cessation
-
2021
- 2021-07-28 ZA ZA2021/05338A patent/ZA202105338B/en unknown
- 2021-07-28 ZA ZA2021/05339A patent/ZA202105339B/en unknown
- 2021-08-02 IL IL285311A patent/IL285311A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009444A (es) | Derivados de imidazo [2,1-f] [1,2,4] triazin-4-amina como agonista de tlr7. | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| DOP2022000124A (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| MX2025000271A (es) | Inhibidores de kras de anillo fusionado para el tratamiento de enfermedades | |
| CL2019000941A1 (es) | Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret. | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| ECSP21034668A (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer | |
| CO2022017622A2 (es) | Inhibidores de quinasa nek7 | |
| UY39625A (es) | Derivados tricíclicos útiles como inhibidores de parp7 | |
| MX2018012165A (es) | Metodos de tratamiento de canceres pediatricos. | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2020010618A (es) | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. | |
| MX2021007565A (es) | Composiciones y metodos para la terapia contra el cancer. | |
| MX394882B (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta) | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| CO2025002794A2 (es) | Combinaciones de compuestos antineoplásicos que comprenden un compuesto bifuncional con actividad inhibitoria de kras mutante g12d | |
| CL2025000396A1 (es) | Combinaciones antineoplásicas que comprenden quimioterapia. | |
| MX2022006179A (es) | Derivados macrociclicos de indol como inhibidores de mcl-1. |